TScan Therapeutics takes in $100M
January 26, 2021- Share:
TScan Therapeutics has raised a $100 million Series C from investors including BlackRock, Bessemer Venture Partners, GV and Novartis Venture Fund. Based in the Boston area, the company is developing T cell-based treatments for solid and liquid tumors and autoimmune and infectious diseases. In January 2020, TScan was valued at $82 million, according to PitchBook data.
Additional Investors
- Share:
-
-
-
-